Vericel Corp VCEL
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. 10-K, Item 1
- Headquarters
- Burlington, MA
- Next results
- around Jan 12, 2027
Where each dollar of revenue went, FY2025
Revenue of $276.3M through the costs to a net profit of $16.5M · income statement of the 10-K
VCEL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
24 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +37.9% ($61.4M to $84.6M) vs revenue +16.5% ($237.2M to $276.3M), +21.4 pts apart
-
Cash from operations $51.9M vs net income $16.5M (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +1.1% ($17.4M to $17.6M) vs revenue +16.5% ($237.2M to $276.3M), -15.4 pts apart
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Contractual Allowances Related to MACI Implant Sales Subject to Third Party Reimbursement
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
24 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Market acceptance of any future product candidates (including MACI Ankle, for which we initiated a clinical trial in the fourth quarter of 2025), if approved, will not be fully known until after they are launched and may be negatively affected by a
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
If we do not effectively expand and train our direct sales force, we may be unable to add new customers or increase sales to our existing customers, and our business will be adversely affected. During 2025, we began an expansion of our MACI sales force. Our ability to achieve significant revenue growth will depend, in large part, on our…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Additionally, several of our ongoing clinical trials utilize an “open-label” trial design. An “open-label” clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Under the Orphan Drug Act, the FDA may grant orphan designation to drugs or biologics intended to treat a rare disease or condition, generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or affects more than 200,000
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $164.4M | $197.5M | $237.2M | $276.3M |
| Net income | −$16.7M | −$3.2M | $10.4M | $16.5M |
| Operating cash flow | $17.7M | $35.3M | $58.2M | $51.9M |
| Free cash flow | $10.1M | $15.3M | −$5.8M | $24.7M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$276.3M ▲ 16.5% in FY2025$16.5M ▲ 59.4% in FY2025$24.7M in FY2025
Recent filings
16 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 13, 2026SIEGAL JONATHAN (Officer) gave notice of a planned sale of 1,885 shares worth about $109K Form 144, approximate sale date Nov 13, 2026
-
Planned saleNov 12, 2026Mara Joseph Anthony Jr (Officer) gave notice of a planned sale of 8 shares worth about $478 Form 144, approximate sale date Nov 11, 2026, under a 10b5-1 plan adopted Dec 2, 2025
-
Planned saleNov 10, 2026MCLAUGHLIN KEVIN F (Director) gave notice of a planned sale of 7,000 shares worth about $409K Form 144, approximate sale date Nov 10, 2026, under a 10b5-1 plan adopted May 12, 2025
-
Planned saleNov 9, 2026Mara Joseph Anthony Jr (Officer) gave notice of a planned sale of 25,000 shares worth about $1.5M Form 144, approximate sale date Nov 9, 2026, under a 10b5-1 plan adopted Dec 2, 2025
-
Planned saleNov 9, 2026ZERBE ROBERT L MD (Director) gave notice of a planned sale of 2,000 shares worth about $116K Form 144, approximate sale date Nov 9, 2026, under a 10b5-1 plan adopted May 19, 2026
About the company
Vericel Corp, Burlington, MA · from the 10-K filed Feb 26, 2026
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S.
- Headquarters
- Burlington, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- MI
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.